Genentech says its MS treatment worked in 3 studies
AP - Thu Oct 08, 2:33PM CDT
NEW YORK (AP) — Genentech released the results Thursday of three late-stage studies of a multiple sclerosis treatment that showed improved symptoms in patients compared with an established treatment.
PFE: 33.24 (+0.15)
EMD Serono Announces Recipients of the Third Annual EUR 1 Million Grant for Multiple Sclerosis Innovation
PR Newswire - Thu Oct 08, 2:00PM CDT
EMD Serono, the U.S. biopharmaceutical business of Merck KGaA, Darmstadt, Germany, today announced the recipients of the third annual Grant for Multiple Sclerosis Innovation (GMSI) at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) being held in Barcelona, Spain.
Merck KGaA, Darmstadt, Germany, and Pfizer Announce Investigational Immunotherapy Avelumab Receives FDA Fast Track Designation for Metastatic Merkel Cell Carcinoma
Business Wire - Wed Oct 07, 6:00AM CDT
--Fast Track designation highlights the serious, unmet medical need that exists for patients with this disease
PFE: 33.24 (+0.15)
Global Market Study on 3D Cell Culture 2015: Asia to Witness Highest Growth by 2020
M2 - Wed Oct 07, 4:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/drlbwb/global_market) has announced the addition of the "Global Market Study on 3D Cell Culture: Asia to Witness Highest Growth by 2020" report to their offering. The global 3D cell culture market was valued at US$ 586.1 Mn in 2014 and is projected to expand at a CAGR of 29.1% to account for US$ 2,717.6 Mn by 2020. 3D cell culture refers to a process of growing cell culture in a 3D environment. It provides a 3D view of the cells grown which helps to analyze cell culture in a better way. 3D cell culture accurately stimulates normal cell morphology, proliferation, differentiation, and migrations and thus, is better suited to study disease models by cellular modeling different disease states. Globally, the 3D cell culture market is witnessing significant growth due rising investments by major players in the market, increasing research related activities, and rising demand for organ transplantation. Moreover, 3D cell culture's ability to replace the animal in research and pharmaceutical testing is also driving the growth of the market. However, factors such as budgetary constraints faced by small and medium-sized laboratories and lack of consistency in 3D cell culture products are restraining the growth of the global 3D cell culture market. Europe has the largest market for 3D cell culture. Extracellular matrices or scaffolds are the largest segments in the overall 3D cell culture market. On the basis of the end user, biotechnology and biopharmaceutical industries dominate the 3D cell culture market. The Europe 3D cell culture market was valued at US$ 234.4 Mn in 2014 and is expected to account for US$ 1,067.8 Mn by 2020 at a CAGR of 28.7%. One of the latest trends that have been observed in the 3D cell culture market is increasing usage of laboratory automation for 3D cell culturing. Some of the major players in the 3D cell culture market are Sigma-Aldrich Corporation, Thermo Fisher Scientific, Inc., Corning Incorporated, and Becton, Dickinson and Company, 3D Biotek LLC, Lonza Group, 3D Biomatrix, Inc. Key Topics Covered: 1 Preface 2 Market Synopsis 3 Porter's Five Forces Analysis 4 Market Overview 5 Global Market Size and Forecast 6 Market Size and Forecast by Technology 7 Market Size and Forecast by Application 8 Market Size and Forecast by End User 9 Market Size and Forecast by Geography 10 Competitive Scenario 11 Company Profiles - 3D Biomatrix, Inc. - 3D Biotek LLC - Becton, Dickinson and Company - Corning Incorporated - Global Cell Solutions, Inc. - InSphero AG - Lonza Group - Reinnervate Ltd (A subsidiary of ReproCELL) - Sigma-Aldrich Corporation (A subsidiary of Merck KGaA) - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/dr...bal_market
SIAL: 139.65 (+0.04)
Global Indolent Lymphoma Pipeline Review, H2 2015 - 17 Companies & 25 Drug Profiles
M2 - Wed Oct 07, 3:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q2nmbb/indolent_lymphoma) has announced the addition of the "Indolent Lymphoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Indolent Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Indolent Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Altor BioScience Corporation - Astellas Pharma Inc. - Bayer AG - Biothera, Inc. - Boehringer Ingelheim GmbH - Celgene Corporation - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Juno Therapeutics Inc. - Kite Pharma, Inc. - MedImmune, LLC - Merck & Co., Inc. - Merck KGaA - MorphoSys AG Drug Profiles - acalisib - ALT-803 - bendamustine hydrochloride - BI-836826 - CC-122 - copanlisib hydrochloride - DI-B4 - duvelisib - entospletinib - ibrutinib - idelalisib - Imprime PGG - INCB-39110 - INCB-40093 - INCB-50465 - JCAR-015 - KTE-C19 - lenalidomide - MEDI-0680 - MEDI-551 - MEDI-551 MEDI-0680 - MOR-208 - obinutuzumab - venetoclax - vorinostat For more information visit http://www.researchandmarkets.com/research/q2...t_lymphoma
KITE: 63.33 (+0.26), GILD: 100.65 (-0.16), MRK: 50.95 (-0.07), INCY: 105.00 (+1.56), JUNO: 48.64 (+0.84), INFI: 8.37 (+0.48), ABBV: 55.64 (-0.40), CELGZ: 1.74 (+0.04)
Global Systemic Lupus Erythematosus Pipeline Review, H2 2015 - 54 Companies & 84 Drug Profiles
M2 - Wed Oct 07, 3:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m4734s/systemic_lupus) has announced the addition of the "Systemic Lupus Erythematosus - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Systemic Lupus Erythematosus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Lupus Erythematosus and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Ablynx NV - Actelion Ltd - AiCuris GmbH & Co. KG - Amgen Inc. - Anthera Pharmaceuticals Inc. - Argos Therapeutics, Inc. - Biogen, Inc. - Biotest AG - Bristol-Myers Squibb Company - Celgene Corporation - Cellular Biomedicine Group, Inc. - Chong Kun Dang Pharmaceutical Corp. - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Genosco - Genovax S.r.l. - GlaxoSmithKline Plc - Hansa Medical AB - ImmuNext, Inc. - Immunomedics, Inc. - Immupharma Plc - Invion Limited - Johnson & Johnson - Kadmon Corporation, LLC - Karyopharm Therapeutics, Inc. - Kineta, Inc. - Lead Discovery Center GmbH - MacroGenics, Inc. - MedAnnex Ltd - MedImmune, LLC - Medsenic - Merck KGaA - Mitsubishi Tanabe Pharma Corporation For more information visit http://www.researchandmarkets.com/research/m4...emic_lupus
MGNX: 23.74 (+0.26), IMMU: 2.17 (+0.12), AMGN: 149.59 (-0.31), GSK: 40.22 (+0.06), BMY: 61.44 (+0.93), JNJ: 95.37 (+0.29), ARGS: 5.80 (-0.18), ANTH: 6.12 (+0.12), ABBV: 55.64 (-0.40), CBMG: 18.62 (+0.05), KPTI: 11.75 (+0.04), CELGZ: 1.74 (+0.04)
Tokalas appoints James B. Breitmeyer, M.D., Ph.D., President & CEO
PR Newswire - Mon Oct 05, 7:00AM CDT
Tokalas, Inc., announced today the appointment of James B. Breitmeyer, M.D., Ph.D. to the position of President & Chief Executive Officer and Board member of the company. Dr. Breitmeyer, a Board certified Medical Oncologist, has over 25 years of experience in the pharmaceutical industry, most recently as President of Bavarian Nordic, Inc. and Executive Vice President of Bavarian Nordic A/S, where he was responsible for securing a $975 MM immuno-oncology commercialization partnership with Bristol-Myers Squibb. He held executive leadership positions at Zogenix Inc., where he remains a Director, Cadence Pharmaceuticals, Inc. (acquired by Mallinkrodt), Applied Molecular Evolution (acquired by Eli Lilly and Company), Serono Laboratories (acquired by Merck KGaA 9/2006), and was the founding President and CEO of the Harvard Clinical Research Institute. He has led efforts resulting in eight FDA and/or international product approvals including Zohydro®, Ofirmev®, Rebif®, Saizen®, Geref®, Serostim®, Fertinex®, and Gonal-F®.
LLY: 86.14 (+2.37), BMY: 61.44 (+0.93)
EMD Serono Announces Grant for Growth Innovation at ESPE in Barcelona
PR Newswire - Sun Oct 04, 10:01AM CDT
EMD Serono, the U.S. biopharmaceutical business of Merck KGaA, Darmstadt, Germany, today announced the recipients of the Grant for Growth Innovation (GGI) for 2015. The awards were handed over during the official award ceremony yesterday evening at the 54th European Society for Paediatric Endocrinology (ESPE) Meeting currently taking place in Barcelona, Spain.
BioMarin Buys Kuvan Drug Rights From Merck
at The Street - Thu Oct 01, 8:15AM CDT
San Rafael, Calif.-based BioMarin says the deal will lift revenue from the PKU metabolic disorder treatment by up to $80 million in 2016.
BMRN: 102.69 (+1.97), SIAL: 139.65 (+0.04)
Savills Studley Represents EMD Serono in One of Largest Suburban Boston Leases of the Year
PRWeb - Wed Sep 30, 8:12AM CDT
Savills Studley is pleased to announce that EMD Serono Inc. the U.S. operating entity of Merck KGaA, has renewed its headquarters lease at One Technology Place in Rockland, MA for 202,000 square feet, becoming the second largest lease agreement in suburban Boston in 2015.
EMD Serono Advances Medical and Scientific Leadership and Entry into Oncology, Appointing Joseph Leveque, M.D. as U.S. Chief Medical Officer
PR Newswire - Tue Sep 29, 8:14AM CDT
EMD Serono, the U.S. biopharmaceutical business of Merck KGaA, Darmstadt, Germany, announced today the appointment of Joseph Leveque, M.D. as U.S. Chief Medical Officer. In this role, Dr. Leveque will be responsible for working with the regulatory, medical and development teams to enhance EMD Serono's clinical presence in the U.S. and to drive the execution of key medical initiatives.
EMD Serono Announces Pioneering Researchers Awarded with $1.1 Million Through Grant for Oncology Innovation Initiative
PR Newswire - Mon Sep 28, 9:59AM CDT
EMD Serono, the U.S. biopharmaceutical business of Merck KGaA, Darmstadt, Germany, today announced the winners of the 2015 Grant for Oncology Innovation (GOI), who will receive grants totaling $1.1 million.
Sigma-Aldrich and Merck KGaA, Darmstadt, Germany, Making Progress Toward Completion of Planned Acquisition
PR Newswire - Mon Sep 28, 6:00AM CDT
Sigma-Aldrich Corporation (NASDAQ: SIAL) announced today it is making progress toward closing the planned acquisition of the Company by Merck KGaA, Darmstadt, Germany. The closing is now expected within the next two months.
SIAL: 139.65 (+0.04), MRK: 50.95 (-0.07)
China Pharmaceutical Market Overview 2015
M2 - Fri Sep 25, 8:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tfbszd/the) has announced the addition of the "The Pharmaceutical Market: China" report to their offering. We remain bullish on China's pharmaceutical sector despite the slowdown in the economy and political reshuffle. We do not think the reshuffle will have any adverse changes or cause any reversals to healthcare reform given that the country has been rolling out various healthcare schemes and that a key person overseeing these healthcare reform plans is Vice Premier Li Keqiang, the man who may potentially take over from Premier Wen Jiabao in the reshuffle. However, the business environment will potentially be threaten by cost- containment policies as the country will have to contain its ever-growing healthcare expenditure. Risk/Reward Rating China continues to rank fourth out of the 18 key markets in Q1 Asia Pacific Pharmaceutical Risk/Reward Ratings with an unchanged score of 62.5 Its high ranking on the table (just behind developed markets Japan, South Korea and Australia) is largely due to the strong growth potential of the pharmaceutical market that is underpinned by a large and increasingly affluent population and an increasing burden of non-communication diseases. Competitive Landscape The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors. Key Topics Covered: 1. SWOT 2. Political 3. Economy 4. Operational Risk 5. Industry Forecast 6. Pharmaceutical Market Forecast 7. Healthcare Market Forecast 8. Prescription Drug Market Forecast 9. Patented Drug Market Forecast 10. Generic Drug Market Forecast 11. OTC Medicine Market Forecast 12. Pharmaceutical Trade Forecast 13. Key Risks To The Forecast Scenario 14. Macroeconomic Forecasts 15. Economic Activity 16. Industry Risk Reward Index 17. Asia Pacific Risk/Reward Index 18. China Risk/Reward Index 19. Rewards 20. Risks 21. Market Overview 22. Industry Trends And Developments 23. Epidemiology 24. Healthcare Sector 25. Research And Development 26. Clinical Trials 27. Biotechnology Sector 28. Regulatory Development 29. Regulatory Regime 30. Intellectual Property Issues 31. Pricing Regime 32. Reimbursement Regime 33. Competitive Landscape 34. Pharmaceutical Wholesale 35. Recent Developments Companies Mentioned - AstraZeneca - Bayer - China Shijiazhuang Pharmaceutical Group - Eli Lilly - GlaxoSmithKline - Merck & Co - Merck KGaA - North China Pharmaceutical Corporation - Novartis - Pfizer - Roche - Sanofi - Shanghai Pharmaceutical - Sinopharm For more information visit http://www.researchandmarkets.com/research/tfbszd/the
MRK: 50.95 (-0.07), LLY: 86.14 (+2.37), GSK: 40.22 (+0.06), NVS: 91.90 (-0.71)
Mexico Pharmaceutical Market Overview 2015
M2 - Fri Sep 25, 8:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gw7lmm/the) has announced the addition of the "The Pharmaceutical Market: Mexico" report to their offering. The improving regulatory environment and the increasing foreign direct investment make Mexico's pharmaceutical market more attractive to multinational drugmakers. We project an increase in government healthcare spending to further boost the number of procedures and expand access to medicines in its national health insurance programme. However, the potential deceleration of the country's macroeconomic growth may dampen the country's pharmaceutical market prospects. Generic drug competition and counterfeit medicines are also key concerns for multinationals pharmaceutical companies. Risk/Reward Rating: The Pharmaceutical and Healthcare Risk/Reward Rating (RRR) in Q113 for Mexico remains the same (58.4) as in Q4. Mexico still ranks the fourth out of the 17 Americas markets surveyed in our proprietary regional RRR rating system above Brazil, indicating a more optimistic outlook for Mexican market. Competitive Landscape: The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors. Companies Mentioned - Bayer - Boehringer Ingelheim - Bristol-Myers Squibb - Eli Lilly - Genomma Labs - GlaxoSmithKline (GSK) - Merck KGaA - Novartis - Pfizer - Roche - Sanof For more information visit http://www.researchandmarkets.com/research/gw7lmm/the
LLY: 86.14 (+2.37), GSK: 40.22 (+0.06), BMY: 61.44 (+0.93), NVS: 91.90 (-0.71)
Merck KGaA, Darmstadt, Germany, and Pfizer Announce FDA Orphan Drug Designation for Investigational Immunotherapy Avelumab in Merkel Cell Carcinoma
Business Wire - Fri Sep 25, 6:00AM CDT
--Alliance between Merck KGaA, Darmstadt, Germany, and Pfizer continues to dedicate significant resources to accelerate clinical program for high-priority investigational anti-PD-L1
PFE: 33.24 (+0.15)
Merck KGaA, Darmstadt, Germany, and Pfizer Collaborate with Dako, an Agilent Technologies Company, on Development of Companion Diagnostic for Investigational anti-PD-L1 Antibody, Avelumab
Business Wire - Thu Sep 24, 4:00PM CDT
As part of the global strategic alliance between Merck KGaA, Darmstadt, Germany, and Pfizer to jointly develop and commercialize avelumab*, an investigational immune checkpoint inhibitor, the companies have announced today that they have a collaboration agreement in place with Dako, an Agilent Technologies company, for the development of a potential companion diagnostic test (CDx).
PFE: 33.24 (+0.15)
New Rebif® (interferon beta-1a) Data at ECTRIMS Highlights the Importance of Disability and Imaging Predictors for Long Term Outcomes
PR Newswire - Thu Sep 24, 8:36AM CDT
EMD Serono, the U.S. biopharmaceutical business of Merck KGaA, Darmstadt, Germany, today announced that data about Rebif® (interferon beta-1a), the company's high-dose, high-frequency interferon beta for relapsing forms of multiple sclerosis will be presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), taking place October 7-10 in Barcelona, Spain. The new data will help healthcare professionals and patients to make informed therapeutic treatment decisions and better understand the impact of Rebif in patients with relapsing forms of MS.
Patterning Material Market by Type & Application - Global Forecasts to 2020 for the $3.8 Billion Industry
M2 - Fri Sep 18, 6:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ns8nhv/patterning) has announced the addition of the "Patterning Material Market by Type , by Application - Regional Forecasts to 2020" report to their offering. The total market size for patterning material is projected to reach USD 3,862.44 Million by 2020 from USD 2,750.00 Million in 2014, at a CAGR of 5.85% between 2015 and 2020 The major driving factors for the market are the rapidly growing Integrated Circuit (IC) market and technological advancement facilitating the era of nanodevices. The new era of miniaturized semiconductor devices also acts as growth driver for the photoresists market. The major challenge for the market is to encounter the cost-related problems associated with the lithography process. The major opportunities for the market are present in the developing economies that are expected to possess strong demand for electronic products such as mobile, tablets, and so on in the near future. Market players have focus on enhancing their product portfolio through new product/technology development in the period from 2010 to 2015. Other development strategies adopted by market players are capacity expansions, agreements & collaborations, joint ventures, and mergers & acquisitions. Scope of the Report By Type: - I-line and g-line - Positive 248nm - Positive 193nm dry resist - Positive 193nm immersion resist - Others By Application: - DRAM - Automotive sensors - MEMS & NEMS Devices - Glass Printed Circuit Boards - Others Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Patterning Material Market, By Type 8 Patterning Materials Market, By Application 9 Patterning Material Market, By Region 10 Competitive Landscape 11 Company Profiles - Brewer Science, Inc. - Dongjin Semichem Co., Ltd. - Fujifilm Holdings Corporation - Honeywell Electronic Materials, Inc. - JSR Micro, Inc. - Merck KGAA - Microchem Corporation - Shin-Etsu Chemical Co., Ltd. - Sumitomo Chemicals Co., Ltd. - The DOW Chemical Company - Tokyo Ohka Kogyo Co., Ltd. For more information visit http://www.researchandmarkets.com/research/ns8nhv/patterning
HON: 101.16 (+0.09)
EMD Millipore Introduces Enhancements to its EMPROVE® Program of Pharmaceutical Raw Materials to Facilitate Risk Assessment
PR Newswire - Mon Sep 14, 7:00AM CDT
EMD Millipore, the Life Science business of Merck KGaA of Darmstadt, Germany, today introduced enhancements to its industry-leading EMPROVE® portfolio of pharmaceutical raw materials. The expanded documentation and regulatory information facilitates drug product manufacturers' risk assessment workflows and supplier qualification. The enhancements also help drug product manufacturers meet their own internal quality guidelines as well as those recently published by the European Commission. This was the first regulatory body to formalize risk assessment requirements for pharmaceutical excipients, despite the practice being common in industry.